New drug combo aims for Longer-Lasting relief in Tough-to-Treat blood disorder
NCT ID NCT07400250
Summary
This study is testing whether combining two drugs, orelabrutinib and romiplostim, can help people with chronic immune thrombocytopenia (ITP) achieve better and longer-lasting control of their condition. It is for adults who have already tried at least one other treatment. The main goal is to see if this combination can improve platelet counts and allow some patients to eventually reduce or stop their medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100010, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.